TY - JOUR
T1 - Combination vaccines
T2 - Defining and addressing current safety concerns
AU - Halsey, N. A.
N1 - Funding Information:
Financial support: Dr. Halsey has received funding from GlaxoSmithKline to support research of a combination diphtheria-tetanus-pertussis, Haemophilus influenzae type b, and hepatitis B vaccine in developing countries. Dr. Halsey has also received an honorarium for participating in a roundtable discussion on combination vaccines.
PY - 2001/12/15
Y1 - 2001/12/15
N2 - Combination vaccines have been in use for >50 years. Historical problems with vaccines, including intussusception after rotavirus vaccine, carrier suppression with tetanus toxoid conjugate vaccines, and decreased immunogenicity of some Haemophilus influenzae type b conjugate vaccines when mixed with acellular pertussis-diphtheria-tetanus, have contributed to some misperceptions about current vaccines. There is no evidence that adding additional vaccines through combination products increases the burden on the immune system, which has the capability of responding to many millions of antigens. Combining antigens usually does not increase adverse effects - in fact, it can lead to an overall reduction in adverse events. Combination products simplify immunization and allow for the introduction of new vaccines without requiring the vaccinee to make additional visits to his or her health care provider. Licensed combination vaccines undergo extensive testing before approval by the United States Food and Drug Administration to assure that the new products are safe and effective.
AB - Combination vaccines have been in use for >50 years. Historical problems with vaccines, including intussusception after rotavirus vaccine, carrier suppression with tetanus toxoid conjugate vaccines, and decreased immunogenicity of some Haemophilus influenzae type b conjugate vaccines when mixed with acellular pertussis-diphtheria-tetanus, have contributed to some misperceptions about current vaccines. There is no evidence that adding additional vaccines through combination products increases the burden on the immune system, which has the capability of responding to many millions of antigens. Combining antigens usually does not increase adverse effects - in fact, it can lead to an overall reduction in adverse events. Combination products simplify immunization and allow for the introduction of new vaccines without requiring the vaccinee to make additional visits to his or her health care provider. Licensed combination vaccines undergo extensive testing before approval by the United States Food and Drug Administration to assure that the new products are safe and effective.
UR - http://www.scopus.com/inward/record.url?scp=0035893113&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035893113&partnerID=8YFLogxK
U2 - 10.1086/322567
DO - 10.1086/322567
M3 - Article
C2 - 11709765
AN - SCOPUS:0035893113
SN - 1058-4838
VL - 33
SP - S312-S318
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - SUPPL. 4
ER -